Q3 2021 Investor Relations Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
4
ESG
Accelerated ESG efforts toward increasing access to medicines,
improving health equity and achieving net-zero carbon emissions
1
Access in LMICS
Reached nearly
29m patients to date
in 2021 through our
flagship programs and
strategic innovative
brands
2
R&D
Achieved positive Ph2b
for next generation
antimalarial therapy
ganaplacide in
combination with
lumefantrine
3
Health equity
Announced a planned
10-year commitment
with historically black
colleges and universities
in US to address root
causes of systemic
disparities in health
outcomes
4
Environment
Committed to achieving
net zero carbon
emissions based on
Science-Based Targets
across our value chain
by 2040
22 Investor Relations | Q3 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation